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Abstract 
A robust dithiocarbamate tether allows novel gadolinium units based on DOTAGA (q = 1) to 
be attached to the surface of gold nanoparticles (2.6 - 4.1 nm diameter) along with functional 
units offering biocompatibility, targeting and photodynamic therapy. A dramatic increase in 
relaxivity (r1) per Gd unit from 5.01 mM−
1 s−1 in unbound form to 31.68 mM−1 s−1 (10 MHz, 
37 °C) is observed when immobilised on the surface due to restricted rotation and enhanced 
rigidity of the Gd complex on the nanoparticle surface. The single-step synthetic route provides 
a straightforward and versatile way of preparing multifunctional gold nanoparticles, including 
examples with conjugated zinc-tetraphenylporphyrin photosensitizers. The lack of toxicity of 
these materials (MTT assays) is transformed on irradiation of HeLa cells for 30 minutes (PDT), 
leading to 75% cell death. In addition to passive targeting, the inclusion of units capable of 
actively targeting overexpressed folate receptors illustrates the potential of these assemblies as 
targeted theranostic agents. 
 




Nanoparticles have found widespread use in medicine to address applications such as 
imaging,1,2 therapy3,4 and drug delivery.5 Superparamagnetic iron oxide nanoparticles 
(SPIONs) such as Feridex/Endorem and Resovist have been approved for clinical use while 
other nanoparticle-based formulations are undergoing clinical trials.6 Gold nanoparticles 
(GNPs) are amongst the most studied due to their biocompatibility, the ease with which their 
dimensions can be controlled and the well-established methods for attachment of surface units 
through sulfur linkages (principally thiols).7 The thermal response to near-IR light irradiation 
of gold nanostructures (photothermal therapy, PTT) has also attracted interest, but it is less 
established than the more widely-used photodynamic therapy (PDT), where cytotoxic singlet 
oxygen / radicals are generated by the photoexcitation of photosensitizers administered to the 
patient.8 The accumulation of gold nanoparticles at tumour sites due to their leaky, immature 
vasculature with wider fenestrations than normal mature blood vessels, known as the enhanced 
permeability and retention (EPR) effect,9 has led to the increasing use of GNPs in cancer 
therapy.10 
This passive targeting imbues nanostructures with a great advantage over smaller, 
molecular substrates. In conjunction with this effect, the selectivity of the material for certain 
cell types can be dramatically increased by the addition of targeting surface units, such as 
aptamers or antibodies.11 Gold nanostructures bearing aptamers show very specific protein 
binding, bringing the material into the proximity of the target protein, allowing targeting to be 
combined with therapy (such as PTT) to achieve localised destruction of cells.12-14 
Magnetic resonance imaging (MRI) is a non-invasive technique that exploits the same 
principles as NMR to acquire detailed anatomical images with the highest spatial resolution of 
all the imaging modalities. In the body, different tissue types possess diverse fundamental 
relaxation parameters (T1/T2) as a result of their different proton densities. This intrinsic 
contrast allows a detailed anatomical image to be acquired using MRI. Contrast agents are often 
used to enhance the image and allow finer detail to be revealed and this is particularly important 
in the early diagnosis of pathologies such as cancer. Contrast enhancement occurs through the 
acceleration of the relaxation of water protons localised in the surrounding tissue. This can be 
achieved by the presence of an exogenous paramagnetic species, as T1 recovery and T2 decay 
are affected by the local magnetic moment. A more effective contrast agent results in larger 
relaxivity values (in mM−1 s−1) as a function of concentration.15 Most clinically-used contrast 
agents are based on paramagnetic (4f7) gadolinium(III) ions, which interact with water 
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molecules to improve the relaxation rates of the protons, enhancing the image contrast.15 The 
immobilisation of trivalent gadolinium units on the surface of gold nanoparticles dramatically 
increases the relaxation rate experienced by the protons of the water molecules in their 
vicinity.16-29 This can be partly traced to the effect on the rotational correlation time, which 
increases when the assembly rotates slowly, leading to greatly increased relaxivity per Gd(III) 
ion. In addition to this intrinsic enhancement, the presence of many gadolinium ions creates a 
multimeric effect on the relaxation of water protons due to the increased localised contrast 
agent concentration.15-33 
All current clinically-approved gadolinium magnetic resonance contrast agents (such 
as DotaremTM, shown in Fig. 1a) are extracellular probes with a non-specific biodistribution. 
One of the aims of the research described here is to add to the development of a new generation 
of contrast agents, which are able to recognise early reporters of a given pathology on the 
cellular surface. The targeting of overexpressed membrane receptors using MRI is hampered 
by the very low concentration of such receptors and by the relatively low sensitivity of Gd(III) 
contrast agents. This limitation can be overcome through the accumulation of a large number 
of imaging moieties (hundreds of Gd units) at the target site through active recognition by 
neighbouring surface units on the nanoparticle (e.g. folic acid). 
 
 
Figure 1. Design of a) clinically-approved contrast agent, DotaremTM (q = 1), b) hexa-
coordinate Gd chelate (q = 3) with dithiocarbamate tether (shown in red), c) the previously 
reported neutral octa-coordinate Gd chelate (q = 1) with dithiocarbamate tether and d) the 
anionic octa-coordinate Gd chelate (q = 1) reported in this work. 
 
Our interest in the surface functionalisation of gold nanoparticles (GNPs) with metal 
began in 2008,34 and since then much of our work33-38 has focused on the use of dithiocarbamate 
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(R2NCS2) tethers as an alternative to the ubiquitous thiol(ate) or disulfide attachment 
methodologies for GNPs. Competition experiments38,39 have demonstrated that 
dithiocarbamates are able to displace thiol(ate)s from the surface of the nanoparticle, but not 
vice versa. This more robust attachment methodology is gaining popularity but there are still 
relatively few examples of metals being tethered to GNPs this way.40 Computational 
approaches using Au20 nanoclusters have helped to provide a rationale for the more robust 
attachment observed.41 These investigations reveal that there is much less distortion and 
reorganisation of the gold atoms when dithiocarbamate units are introduced to the Au20 surface 
compared to the case for thiolates. With dithiocarbamates, no evidence is found for the 
‘stapling’ effect with thiolates, which has been observed structurally by Kornberg and co-
workers in the crystal structure of Au102(SC6H4CO2H-4)44 nanoparticles (diameter 1.6 nm).
42 
‘Staples’ form when a gold atom is lifted from the assembly and pinned between the two nearest 
thiolates, potentially making it prone to loss, for example as a molecular [Au(SR)2] unit 
(observed experimentally).43 Though often not acknowledged (and quite possibly overlooked 
or ignored), the attachment through a single thiol(ate) tether often leads to detachment from 
the nanoparticle surface and this is likely to be exacerbated under physiological conditions. 
The performance of molecular contrast agents can be dramatically enhanced by increasing the 
mass of the assembly and this has been achieved through attachment to polymers, liposomes 
or nanoparticles, or through the formation of multimetallic (metallostar) motifs.15 This has been 
widely used in conjunction with approaches to reduce the freedom of rotation of the Gd(III) 
units to further enhance the relaxation imparted to the protons of the nearby water molecules.  
In 2014, we reported the first example of dithiocarbamates being used to attach 
gadolinium units to GNPs for potential use in MRI imaging.33 These materials (Fig. 1b) showed 
promising relaxivities, however, the hexadentate coordination of the Gd3+ ion (q = 3) 
undermined their application due to the potential for loss of the toxic gadolinium ions under 
physiological conditions. This was a major factor in the improved design we have described 
previously,44 based on an octadentate coordination environment (Fig. 1c), similar to Dotarem™ 
(Fig. 1a).45 However, unlike Dotarem™, the resultant Gd chelate (Fig. 1c) is neutral rather than 
anionic. This could lead to a weaker interaction between the amide carbonyl lone pair and the 
Gd(III) centre, potentially impacting on the relaxivity performance and the complex stability. 
In addition, it has been shown45 that macrocyclic chelates with carboxylate arms have faster 
water exchange rates (contributing to higher relaxivity) than macrocyclic chelates with amide 
arms. These factors were key to our new chelate design, which contains carboxylate arms and 
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no amide donors. This modification is also significant as it creates the same coordination 
environment found in a leading contrast agent in widespread clinical use, DotaremTM. This 
similarity to a clinically-approved compound also provides reassurance (particularly in the 
context of Nephrogenic Systemic Fibrosis, NSF) that the toxic gadolinium(III) ion will not be 
released under biological conditions. The considerations outlined above led to the design of a 
new anionic gadolinium(III) chelate (Fig. 1d) with carboxylate donors and a dithiocarbamate 
tether. 
In the context of a multifunctional surface, this approach exploits the most robust tether 
(dithiocarbamate) to attach the most critical surface unit, the imaging modality. In an 
orthogonal approach, additional groups can then be secured using less robust (di)thiol(ate) 
groups, providing biocompatibility, targeting and a therapeutic function. The straightforward 
synthesis combined with the versatility offered by a modular design, gives access to a wide 
range of materials that can be used as a platform for combined imaging and therapy. In this 
report, the well-defined nature of the surface units, synthesised separately, is matched by the 
polyfunctionalisation of the GNPs, allowing the relaxivity and other properties to be correlated 
to the design. 
 
Results and discussion 
Synthesis of a novel gadolinium surface unit 
The new chelate 9 was prepared by a straightforward multi-step route (Scheme 1) starting from 
5, generated in three steps from commercially-available cyclen.46-48 All new compounds (6 - 
9), were fully characterised by a combination of 1H NMR spectroscopy, 13C{1H}NMR 





Scheme 1. Synthesis of the new macrocycle 9 from known DOTAGA precursor 5. 
 
Addition of the gadolinium to 7 was performed using GdCl3·6H2O and was followed 
by removal of any free (toxic) gadolinium ions as Gd(OH)3, precipitated under basic conditions 
(Xylenol orange test). Infrared spectroscopic and mass spectrometry data were consistent with 
the formation of complex 8 (Scheme 1), which was found to be stable indefinitely as a solid 
and was prepared on a large scale (> 1 g). It is known that generation of the dithiocarbamate 
from the amine greatly increases its reactivity so precursor 8 was used for storage of the surface 
unit. When desired, the addition of K2CO3 followed by carbon disulfide, leads to the in situ 
formation of the expected dithiocarbamate moiety (9), in line with our previous studies on 
piperazine-based dithiocarbamate complexes.35,36,38,44,49-55 High-resolution mass spectrometry 
confirmed the generation of 9 (m/z 812.1283 for [M+K]+), while solid state infrared absorptions 
measured for 9 attributed to ν(CN) and ν(CS) at 1427 cm−1 and 1002 cm−1, respectively, 
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provided evidence for the formation of the dithiocarbamate. This was reinforced by a resonance 
at 209.5 ppm in the 13C{1H}NMR spectrum obtained for the diamagnetic lanthanum (La3+, f0) 
analogue of 9, formed in an identical fashion. 
 The performance of 8 as a contrast agent was established using NMRD profiles 
measured with a 0.25 T fast field-cycling NMR relaxometer (see Supporting Information) and 
compared to the current clinically-approved standard, Dotarem™ (Fig. 1a). Perhaps due to the 
slightly higher molecular mass, compound 8 was found to possess a higher relaxivity (Figure 
2). The presence of amide arms in the chelate, as present in our previous design (Figure 1c), 
has been reported to impact negatively on the relaxivity observed.56 It is therefore noteworthy 
that the new design described here for 8, in which the Gd centre is exclusively coordinated by 
carboxylate arms, exhibits superior relaxivity performance compared to the earlier design. 
 
 
Figure 2. NMRD profiles of compound 8 at 25 and 37 °C and Dotarem™ under the same 
conditions. 
 
 The design of the chelate in 8 and 9 is intentionally closely based on that of Dotarem™, 
one of the leading clinically-approved contrast agents. Indeed, in contrast to our previous 
design (Fig. 1c), the anionic nature of the chelate mimics that of Dotarem™ even more closely 
as well as avoiding the use of an amide arm in the chelate. The stability of the chelate towards 
loss of gadolinium ions (and hence its toxicity) was therefore expected to be similar to the 
contrast agents used in the clinic. This was probed by adding Zn2+ ions to 8 and monitoring the 
relaxivity values obtained (Supporting Information), as described by standard literature 
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protocols.57 This revealed no change in the relaxivity even after 45 hours of exposure to excess 
ZnCl2 at 37 °C. Like Dotarem™, fluorescence lifetime measurements for the europium 
analogue of 8 (compound 10) revealed the expected hydration value of q = 1 for the octadentate 
chelate (Supporting Information). The assessment of the gadolinium surface unit was continued 
in cytotoxicity studies. MTT cell viability assays (HeLa cells, 24h) were performed on 8 and 
showed little or no toxicity even at concentrations as high as 250 µM (Supporting Information). 
 
Targeting and therapeutic units 
As well as their stability under a range of physiological conditions, a major advantage of using 
gold nanoparticles is the ability to combine multiple groups on the surface using 
complementary, orthogonal attachment approaches.58 Other platforms, such as molecular 
systems or liposomes, require substantial modifications to allow new combinations of 
imaging/targeting/therapeutic units to be incorporated into assemblies of sizes 2-200 nm, 
resulting in fundamental changes to the design. The nanomaterials reported here combine an 
imaging modality (MRI) with targeting and biocompatibility/stealth features and also a 
photoswitchable therapeutic (PDT) unit. The overarching aim of the programme is to construct 
a library of components (imaging, biocompatibility, targeting, therapy) which can be 
assembled in a straightforward manner to achieve a nanostructure of tuneable size (e.g. 2-200 
nm) with the appropriate functionality to target, image and (selectively) kill specific cells. 
Targeting groups (aptamers, antibodies etc.) can be chosen to recognise specific 
molecules on the cellular surface that act as early reporters of a given pathology. In a 
nanoparticle system such as the one reported here, this can enhance the passive targeting of 
cancerous cells provided by the EPR effect. Both of these targeting approaches would lead to 
a high concentration of Gd units being present in close proximity to the diseased cells. In the 
case of receptor-driven targeting, the high concentration of MRI contrast units would 
compensate for the very low concentration of such receptors (e.g. overexpressed membrane 
receptors) and the relatively low innate sensitivity of Gd(III) contrast agents.59 Once the 
location of the GNPs has been identified (due to their localised contrast enhancement) through 
non-invasive MR imaging, photoexcitation (through the skin or via an endoscope) of the highly 
localised concentration of the photosensitizer immobilised on the surface of the nanoparticles 
would allow selective destruction of diseased tissue. 
In order to explore this targeting concept, a thiol-functionalised folic acid group (FA-
SH, 11) we have previously used44 was added to the assembly to investigate uptake in HeLa 
cells, which express folate receptors on their surface to a greater degree than MCF-7 cells.60 
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More complex alternatives, such as DNA/RNA aptamers, can also be used.12 The modular 
conjugation of different thiol-based targeting moieties (some of which are commercially-
available), tailored to recognise specific proteins or receptors, indicates the versatility of the 
proposed nanoparticles and their potential use as combined imaging and therapy platforms. The 
recognition moiety can be chosen based on the specific target and its intra- or extracellular 
location. 
Porphyrins, such as clinically-approved porfimer sodium (PhotofrinTM), are well known 
for their ability to act as photosensitizers in photodynamic therapy (PDT).61-62 The attachment 
of porphyrins to GNPs for this purpose has been reported, however, almost all designs feature 
a thiol, which could detach under demanding conditions (vide supra). It was therefore decided 
to prepare a new, more robust PDT sensitizer unit for attachment to the surface through two 
contact points. Pioneering work in this area has been performed by Beer and Davis, who 
reported zinc porphyrin assemblies attached to the surface of gold nanoparticles through both 
dithiocarbamate63 and disulfide64 (dithiolate) tethers for application in sensing.  
The known amino-functionalised tetraphenylporphyrin (TPP) 13 was prepared from the 
parent porphyrin (TPP, 12) and coupled to lipoic acid to yield the new compound 14 (Scheme 
2) which was then metallated with Zn(OAc)2 to afford the zinc-TPP (15) in 64% yield from 13. 
The new compounds were fully characterised (1H NMR, 13C{1H} NMR and IR spectroscopy, 
mass spectrometry, elemental analysis and XRD of a derivative – Supporting Information) 
followed by an investigation of the photophysics of 15. This revealed an absorption at 420 nm 
and emission at 650 nm. The disulfide moiety forms a dithiolate on interaction with the gold 
surface, ensuring a strong attachment of the PDT sensitizer surface unit. 
 
 




In addition to the surface units described above for delivery of MRI contrast 
enhancement (9) and PDT (15), PEG-SH and thioglucose were used to enhance the 
functionality of the surface architecture. Poly(ethylene)glycol (PEG) units enhance water-
solubility and biocompatibility, while thioglucose has been suggested to perform a targeting 
function for tumours (due to their higher consumption of glucose)65 as well as conferring water 
solubility.66  
 
Nanoparticle synthesis and functionalisation 
By far the most common method of immobilising Gd units on the surface of gold nanoparticles 
(GNP) is through the use of thiol(ate)s.67-68 It is often assumed that the strength of the Au-S 
interaction precludes their loss from the surface, however, recent results40,69 suggest that the 
loss of thiol(ate)s from the GNP surface does indeed occur. Due to these assumptions, this loss 
of surface units is rarely investigated in the studies of GNPs for medical applications and so 
the extent of this issue remains unclear. The propensity of thiols to form disulfide linkages 
(rather than attach to the gold surface) has also been reported to hamper the effective design of 
Gd-functionalised nanoparticles.67 These issues have led us33,44 to exploit the strong attachment 
of dithiocarbamate tethers to the surface of gold nanoparticles39-41,63,70-86 as the means to attach 
the gadolinium units. The robust attachment of the MRI contrast unit to the GNP surface is 
critical, since detachment will impact negatively on the overall relaxivity of the assembly and 
will undermine the location of the GNP through MR imaging. These considerations led directly 
to the design of 9 described above, which combines the superior strength of attachment 
(compared to thiol(ate)s) provided by the dithiocarbamate unit with limited rotational freedom. 
This rigidity maximises the relaxivity enhancement obtained through the immobilisation of the 
Gd unit on the nanoparticle, while its similarity to clinically approved Dotarem™ should lead 
to similar biological properties for the surface units. 
A general protocol for the synthesis of gold nanoparticles (Scheme 3) was devised 
based on the Brust-Schiffrin method.87 Glassware was washed with aqua regia and rinsed 
thoroughly beforehand. A methanol solution of tetrachloroauric acid was prepared and 
solutions of the various sulfur-based ligands (9, PEG-SH, thioglucose, FA-SH (11) and 15) 
were then introduced in various ratios (0.01 – 0.5 eq. relative to Au). Ultrapure water was used 
to dissolve PEG-SH and thioglucose, while ZnTPP (15) required the use of DMSO. A 1:1 
mixture of ultrapure water and DMSO was used to make a solution of FA-SH and a 1:1 mixture 
of methanol and acetonitrile was used for 9. The mixture was cooled to 4 °C and a fresh solution 
of sodium borohydride in ultrapure water added dropwise to effect reduction from trivalent 
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gold to Au(0). The mixture was stirred at 10 °C for 3 hours, after which the nanoparticles were 
then centrifuged at 5300 rpm for 45 minutes. The supernatant was removed and the 
nanoparticles were rinsed at least 3 times by this method with ultrapure water until the filtrate 
failed to show the presence of the free Gd chelate ligand (9), as determined by measurement of 
relaxivity.  
 
Scheme 3. Synthesis of GNPs with 9, 15 and various surface units (R1-SH, R2-SH, R3-SH). 
 
A total of 10 functionalised GNPs were prepared in a modular fashion with up to five 
different surface units (Figure 3). In addition, the use of three different attachment approaches 
(DTC/dithiolate/monothiolate) ensures that the ‘payload’ of the most significant Gd (9) and 
ZnTPP (15) units is maintained by the strong attachment of the dithiocarbamate and dithiolate 
(respectively) relative to the weaker thiolate Au-S bonds used for other surface features. 
 
 




This approach represents a rapid, straightforward and versatile route to the modular 
preparation of multifunctional gold nanoparticles. The greater strength of attachment 
(compared to thiolates) of the DTC unit (9) ensures the presence of the Gd contrast agent, while 
the use of a disulfide unit for the PDT unit (15) helps prevent loss of the therapeutic unit. All 
surface units were added to the reaction mixture at the same, providing them all with the 
opportunity to bind to the nanoparticle surface. Thermogravimetric analysis (TGA) was 
performed (Supporting Information, Section S6) in an attempt to quantify the surface units 
through loss of mass. However, it was found that no distinct mass loss could be attributed to 
specific surface units. Similarly, solid-state infrared spectroscopy (Supporting Information, 
Section S6.1) was not able to distinguish between the surface units due to their many shared 
features, such as C-O and C=O absorptions. All surface units were added in large excess, with 
respect to the number of gold surface atoms so, although the values in Figure 3 do not represent 
final amounts present on the nanoparticle surface, it is likely that all surface units added are 
represented on the nanoparticle. This is reflected in the different relaxivity and cell uptake 
behaviour observed (vide infra). Once corrected for diameter, it was found that the use of 
increasing numbers of additional surface units causes a decrease in the number of gadolinium 
chelates on the surface of the GNPs, as determined by ICP-OES (Supporting Information, 
Table S9-1). This suggests that the additional surface units are successfully competing for some 
of the surface area, causing fewer Gd units to be present. 
Transmission electron microscopy (TEM) was used to determine the diameter and size 
distribution of the nanoparticles (Figure 4). This revealed a size distribution of between 2.6 and 
4.1 nm in diameter with the different surface units exerting a subtle effect on the sizes obtained. 
The particles displayed a reasonably narrow size distribution but were not monodisperse (Table 
S9-1 in Supporting Information), though the variation in size was not expected to have any 
significant impact on their performance. Dynamic light scattering (DLS) measurements for 
NP5 and NP7 suggested that the hydrodynamic radius increases from 2.6 - 4.1 nm to 
approximately 20 nm due to the PEGylated thiolate surface units (PEG-2000). Energy 
Dispersive X-ray spectroscopy (EDS) was used to identify the presence of Gd, Au and Zn 
(where present) in the assembly (Figure 4). The ratio of Gd, Au and Zn was more accurately 
determined by inductively-coupled plasma optical emission spectroscopy (ICP-OES) and 
allowed the number of Gd units per GNP to be calculated and used for relaxivity measurements. 
TGA for NP1 (just 9 on the surface) was found to be in good agreement with the ICP-OES 
results. Calculations based on the TEM and ICP-OES data for NP1 led to the estimation of 
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between 179 (ICP) and 206 (TGA) Gd units (of 9) per nanoparticle. As no other surface units 
are present, this can be assumed to be close to the maximum possible loading of Gd units for 
this diameter of nanoparticle. 
 
 
Figure 4. TEM (left) and EDS (right) data for NP10. 
 
The surface plasmon resonance (SPR) band was observed in the UV-vis spectrum 
recorded for each assembly at approximately 550 nm, in agreement with the 2.6 - 4.1 nm size 
of the gold core. Zetapotential values ranging between −39.8 and −32.8 (Supporting 
Information) were measured, indicating good stability and resistance to agglomeration. The 
nanoparticles were also found to be stable in solution across a range of pH values between 4 – 
10 (HEPES buffer solution) over a 24 h period. The stability in the presence of NaCl was tested 
in water and monitored by UV-vis spectroscopy, showing no tendency to precipitate over a 
period of 24 h. The same technique was used to analyse their behaviour in biological media, 
which revealed no changes to the data. See Supporting Information for further details.  
 
Relaxivity studies 
With a series of 10 gold nanoparticles functionalised with a range of different surface units to 
hand, the relaxivity of the nanoparticles was measured and NMRD profiles determined. The 
immobilisation of gadolinium units on a polymer or nanoparticle surface has often been 
employed in order to enhance the relaxivity of the individual Gd units as well as the whole 
assembly.66,68 This effect can be traced to the slow tumbling of the much larger unit and a 
reduction in the rotational freedom experienced by each individual Gd unit. The materials 
prepared in this study exhibited a particularly pronounced enhancement of up to 8 times higher 
relaxivity per Gd centre. Part of this boost can be attributed to the rigid nature of the 
dithiocarbamate attachment of chelate 9 to the gold surface, preventing the rotation about either 
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the C-N (multiple bond character) or Au-S bonds. This is demonstrated in the NMRD profile 
of NP1 shown in Figure 5. Designs in which the chelates are attached to the surface through a 
thiol(ate) tether inevitably allow rotation about the axis of the tether and the Au-S interaction.59 
The formation of unwanted disulfide linkages has also been observed which creates flexible 
chains of Gd units anchored at only a few points to the surface.67 Many reports use long PEG-
thiolate chains terminated in a Gd unit, which retain their internal flexibility and so restrict the 
enhancement observed.32,68,88-91 When combined, these effects undermine to some degree the 
benefit of immobilisation on the nanoparticle surface but this is easily overlooked when 
relaxivity is quoted per nanoparticle rather than per Gd centre. 
The effect of immobilising the Gd unit on the nanoparticles is clearly demonstrated by 
the relaxivity performance of NP1. These nanoparticles display a 6.3-fold contrast 
enhancement (NP1) per Gd unit over non-immobilised 8 (r1 = 5.01 mM−
1 s−1 at 10 MHz, 37 
°C), as can be seen from the NMRD profile shown in Figure 5. This represents a relaxivity per 
Gd unit of r1 = 31.68 mM−
1 s−1 and per nanoparticle of r1 = 5691 mM−
1 s−1 for NP1 (both at 10 
MHz, 37 °C). This is one of the highest relaxivity enhancements per Gd ion yet reported for 
gold nanoparticles that could potentially be used in a clinical setting. A slightly higher value 
(r1 ~ 40 mM−
1 s−1 at 10 MHz, 37 °C) was reported by Helm and co-workers68 for gold 
nanoparticles with a surface unit based on a heptadentate chelate with two coordinated water 
molecules (q = 2). The lower than usual coordination number with this polydentate chelate 
make this suitable for pre-clinical but not clinical imaging (nephrogenic systemic fibrosis 
concerns). The enhanced performance of NP1 can be attributed to the internal rigidity of the 
surface unit provided by the multiple bond character present in the C-N bonds of the 
dithiocarbamate and the dual Au-S attachment at the surface (compared to a single Au-S 
attachment for thiolates). The flexibility of the tether attaching the surface unit to the surface 
has been identified92 as the main factor limiting the relaxivity enhancement on immobilising 





Figure 5. NMRD profiles of NP1 and 8 at 25 and 37 °C. 
 
The addition of PEG-SH units improves both the solubility of the GNPs in biological 
media and also enhances their biocompatibility by performing a ‘stealth’ function. This is a 
crucial factor in any clinical application as it prevents premature removal by macrophages.93 
Using a similar procedure to that employed for the synthesis of NP1, a series of materials with 
mixed surface units was prepared (Scheme 3), using just PEG-SH and the Gd unit (NP2). This 
led to a small reduction in relaxivity per Gd ion possibly due to crowding of the Gd centres by 
the PEG units, reducing their exposure to the bulk water. 
In addition to 9, thioglucose was also added in equimolar amounts to PEG-SH to 
generate NP3, which resulted in a triply functionalised surface. Two further PEGylated 
assemblies were functionalised with the thiol-modified derivative of folic acid (FA-SH, 11) 
reported previously44 with no thioglucose (NP4) and an assembly (NP5) with PEG-SH, 
thioglucose and folic acid (FA-SH) (Scheme 3 and Figure 3). 
 Monometallic Gd-based contrast agents, such as clinically-approved Dotarem™ 
(Figure 1) are hampered by the adverse effect on their relaxivity caused by their associated 
short rotational correlation time. Increasing the temperature leads to more rapid tumbling and 
causes a decrease in the r1 value, despite the higher water exchange rate at elevated 
temperatures. For Gd units immobilised on nanoparticles, slower tumbling is indeed achieved, 
however, the potential for enhancement is reduced by undesirable internal rotation, often about 
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the axis of the tether. The rigidity introduced by the dithiocarbamate in our system means that 
an increase in temperature has little impact on the rotation of the Gd surface unit, while still 
allowing the beneficial effects of a higher water exchange rate. This can be seen in Figure 6, 
which plots the relaxation rate (R1) at temperatures between 30 – 70 °C divided by the value at 
30 °C (at 7 MHz) for monometallic 8 and NP1. This reveals the expected decrease in values 
for 8, while the corresponding values for NP1 show an increase in relaxation rate. 
 
 
Figure 6. Plot of the ratio of relaxation rate (R1) at temperatures between 30 – 70 °C compared 
to the value at 30 °C (at 7 MHz) of monometallic 8 and NP1. 
 
With the very promising performance of the Gd unit (9) confirmed along with the 
demonstration that four different surface units can be attached to the surface, the focus moved 
to investigating the relaxivity performance with multiple surface units, including one providing 
a therapeutic action (ZnTPP, 15).  
As a control, an assembly (NP6) was prepared with only Gd (9) and ZnTPP (15). While 
EDS confirmed the presence of both Gd and Zn, the distribution of the two surface units was 
determined to be a 2:5 ratio of Gd and Zn by ICP-OES. This material displayed good relaxivity 
at 10 MHz and 37 °C both per Gd ion (42.21 mM−1 s−1) and overall (3713 mM−1 s−1) and is the 
best performance per Gd unit reported for any comparable (q = 1) chelate. The addition of PEG 
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surface units to aid biocompatibility (NP7) did not undermine the relaxivity performance 
substantially. 
While it would be expected that the increase in complexity of the surface architecture 
must impact on the overall relaxivity per NP, the overall enhancement compared to Dotarem™ 
or compound 8 is still substantial. Less easy to predict is the impact on the relaxivity 
performance per Gd unit. As can be seen in the relaxivity per Gd unit recorded at 37 °C (Figure 
7), the performance of NP1 (only Gd units) is similar to that of NP2 (Gd and PEG units), 
suggesting that the presence of PEG units has no specific effect. As has been noted 
previously,66,94 the presence of thioglucose seems to enhance the relaxivity, possibly through 
the small size of the thioglucose units relieving the crowding of the Gd units, allowing better 
interaction with the bulk water. This is reflected in the increase for NP3 (Gd, PEG and 
thioglucose units), however, the presence of folic acid units seems to have a detrimental effect 
on the r1 values per Gd, as observed for NP4 (Gd, PEG and folic acid units) and NP5 (Gd, 
PEG, thioglucose and folic acid units). The addition of the ZnTPP unit (15) for NP6 – NP10 
seems to lead to an enhancement, perhaps due to these bulky groups reducing the flexibility of 
the Gd units (9) still further. The enhancement of relaxivity per Gd unit on increasing the 
temperature from 25 °C to 37 °C (Section S6 in the Supporting Information) was seen for all 
nanoparticles whereas the r1 value for the Gd unit itself (8) dropped, as is typical for small 
molecular weight monometallic Gd complexes. This can be traced to the greater rigidity 
afforded by the dithiocarbamate and the piperazine tether in our design. This is in agreement 
with our results for other DTC-based Gd units but is in stark contrast to the poorer performance 
at higher temperature exhibited by GNPs decorated with more flexible Gd units.32,68,88-91 At 25 
°C, the best performance is found for the same four nanoparticles (NP3, NP6, NP7, NP8), 
while the performance of the nanoparticles functionalised with folic acid is again the lowest. 
Figure 7. NMRD profiles of NP1 - NP10 and compound 8 in the study per Gd unit shown at 





Figure 7. NMRD profiles of NP1 - NP10 and compound 8 in the study per Gd unit shown at 
37 °C. 
 
The use of additional surface units for other functions (biocompatibility, targeting, 
therapy etc.) should lead to a reduction in the overall relaxivity per nanoparticle due to fewer 
Gd units being present. This is evident in Figure 8, with NP1 (only Gd units), registering the 
highest overall relaxivity values and NP10 (containing all 5 surface units) showing the lowest 
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relaxivity per nanoparticle. The overall r1 value per nanoparticle decreases from 5691 mM−
1 
s−1 for NP1 to 2090 mM−1 s−1 for NP10 (both at 10 MHz, 37 °C). However, these changes must 
also be viewed in terms of the differences in nanoparticle diameter, which range from 2.6 - 4.1 
nm which will have an impact on the loading of Gd ions on the surface. Compared to the 
diffuse and non-localised effect of monometallic species such as Dotarem™, the high local 
concentration of Gd ions created by their manifold presence on the nanoparticle will lead to a 
great localised contrast enhancement, even for the uptake of a single nanoparticle. Uptake and 
selectivity can be enhanced by the other surface units, leading to targeting of the high Gd 
payload to a tumour, for example. The contrast enhancement observed would thus be extremely 
large for even a single receptor (compared to a targeting unit linked to one or only a few Gd 
centres). In addition to their high localised relaxivity, the small diameters of the nanoparticles 
described here should allow good membrane penetration and cellular uptake. 
 
 






Table 1. Summary of relaxivity values (measured at 10 MHz at 37 °C). 
 r1 per Gd / mM
−1 s−1 r1 per NP / mM−1 s−1 
NP1 31.68 5691 
NP2 31.44 3719 
NP3 37.96 2330 
NP4 28.83 4874 
NP5 29.13 2932 
NP6 42.21 3713 
NP7 40.88 2749 
NP8 40.24 2702 
NP9 34.72 2810 
NP10 37.01 2090 
8 5.01 - 
DotaremTM 3.94 - 
 
Magnetic resonance imaging 
The GNPs were imaged on a 1.5 T MRI Scanner (Ingenia, Philips) used for patients at St. 
Thomas’ Hospital, London, UK, in order to investigate their contrast enhancing performance 
at a clinical magnetic field strength. Phantom imaging was carried out using solutions of the 
GNPs in Eppendorf tubes, which demonstrated the ability of the nanoparticles to deliver a 
contrast enhancement far superior to that of Dotarem™ and at a gadolinium concentration of 
only 0.02 mM. Clinical administration of Dotarem™ is typically set at 0.1 mmol/ kg, which 
represents a much higher concentration. Unsurprisingly, the relaxivities (per Gd unit) of the 
GNPs were far greater than the control of Dotarem™, which displayed a relaxivity of 4.6 ± 0.3 
mM−1 s−1. The relaxivities of the GNPs at 1.5 T were all similar in magnitude with values 
ranging from 25 ± 1 mM−1 s−1 (NP5) to 31 ± 3 mM−1 s−1 (NP6) per gadolinium unit (Figure 9). 
These values represent an increase in relaxivity between 5 and 7 times higher than Dotarem™. 
Figure 10 summarises the relaxivity performance of these GNPs over all frequencies recorded. 
 
 
Figure 9. MR images and relaxivity values (per Gd unit, in mM−1 s−1) for Dotarem™, NP1, 




Figure 10. NMRD profiles of Dotarem™, NP1, NP5, NP6 and NP10 (at 25 °C) showing 
relaxivity behaviour (per Gd unit, in mM−1 s−1) between 0.01 MHz and 63.87 MHz (clinical 
field). 
 
The gadolinium chelate reported here (Fig. 1d, compound 9) represents an improvement 
in design compared to that reported previously (Au@DO3A-CS2, Fig. 1c)44 as it is negatively 
charged and possesses only carboxylate arms, making it directly comparable to clinically-
approved Dotarem™. The relaxivities of the nanoparticle-bound chelates shown in Figures 1c 
and 1d (9) are comparable at low magnetic field strengths (0.25 mT – 0.25 T, 0.01 MHz – 10 
MHz) but at a clinically-relevant magnetic field strength of 1.5 T, the new chelate (9) performs 
substantially better when attached to the GNP, with a relaxivity 24% higher than the 
Au@DO3A-CS2 design shown in Figure 1c (29 mM−1 s−1 versus 22 mM−1 s−1, respectively). It 
is possible that due to closer packing of 9 on the nanoparticle surface (2.6 chelates per nm2 
versus 1.6 chelates per nm2 from ICP-OES and TEM data), their motion is restricted more 





Figure 11. NMRD profiles of Dotarem™, NP1 and Au@DO3A-CS2 (at 25 °C) showing 
relaxivity behaviour (per Gd unit, in mM−1 s−1) between 0.01 MHz and 63.87 MHz (1.5 T 
clinical field). 
 
Cell uptake and PDT studies 
The GNPs were found to be non-cytotoxic towards cancerous (HeLa and MCF-7) cell lines at 
gold concentrations up to 250 M (Supporting Information). Measurement of GNP uptake 
inside cells (HeLa and MCF-7) was determined after incubation for 1, 6 and 24 hours with the 
differently functionalised GNPs. The nanoparticles were detected inside the cells (ICP-OES, 
Supporting Information) at varying concentrations, depending on the incubation time and 
composition of the GNP, as shown in Figure 12. 
 
 
Figure 12. Cell uptake studies performed with NP1, NP5, NP7 and NP10 (200 µM) over 




 The data in Figure 12 show that the nanoparticles functionalised with PEG, thioglucose 
and folic acid (NP5) show much greater uptake after 6 and 24 hours than the material with only 
Gd units (NP1). The presence of PEG is known to decrease or delay uptake of nanoparticles 
by cells, however, a comparison of NP1 with NP2 and NP6 with NP7 (given the associated 
error) reveals no such behaviour in this case. The addition of the ZnTPP unit (15) appears to 
hinder the uptake (NP7 and NP10), however, the presence of PEG, thioglucose and folic acid 
surface units ameliorates this effect. HeLa cells express the folate receptor to a greater extent 
than MCF-7 cells,95-97 however, it is the combination of folic acid and thioglucose that appears 
to lead to the greatly enhanced uptake of NP5 (particularly after 6 h, where there was a 
significant difference in uptake between HeLa and MCF-7 cells (p < 0.025)). 
A widefield microscope (FILM, Imperial College) with an LED operating at 570 nm 
was used to investigate the photodynamic therapeutic effect (in HeLa cells) of the GNPs 
bearing ZnTPP surface units. Using 200 M concentrations of NP7 (Gd, PEG and ZnTPP) and 
NP10 (Gd, PEG, thioglucose, folic acid and ZnTPP), the effect of the surface functionality on 
the cellular uptake and performance in PDT was assessed. Since the cytotoxic effect of singlet 
oxygen is only effective when generated within the cell, the greater uptake of NP10 compared 
to NP7 should render this assembly more effective. This is indeed observed in Figure 13, where 
the control is provided by irradiation of the cells in the absence of nanoparticles. After 5 
minutes of irradiation at 570 nm, a decrease in cell viability of around 50% was observed for 
NP10 and only 10% for NP7. After 15 minutes of irradiation, the cells incubated with NP10 
showed a much lower viability of 35% while the NP7 experiment displayed a more modest 
decrease to 58% cell viability. These results can be taken as an illustration of the need for 
sufficient cellular uptake to achieve a significant therapeutic effect. Irradiation for 30 minutes 
in total led to a final cell viability value of around 25% with NP10. 
Figure 13. Cell viability of HeLa cells after irradiation with laser light (570 nm) for 5, 15 and 









Figure 13. Cell viability of HeLa cells after irradiation with laser light (570 nm) for 5, 15 and 
30 minutes following incubation with NP7, NP10 (200 M) or no nanoparticles (control) 
 
Conclusions 
This contribution illustrates how a straightforward synthetic strategy combining orthogonal 
tethering approaches can be used to prepare a series of nanoparticles functionalised with up to 
5 different surfaces units. The increasing strength of the thiolate/dithiolate/dithiocarbamate 
interactions ensure that the key surface units responsible for imaging and therapy are retained. 
In this work, the powerful enhancement effect on relaxivity per Gd unit of immobilising 
trivalent gadolinium complexes on the nanoparticle surface is clearly shown. In order to 
achieve this, a new, non-toxic, anionic, octadentate Gd surface unit (9) has been designed and 
prepared in multigram quantities based on the clinically-approved DOTA scaffold (q = 1). The 
limited flexibility of the tether is key to the enhanced relaxivity observed and this is achieved 
through the multiple bond character of the dithiocarbamate C-N bond and the attachment of 
this 1,1’-dithiolate ligand at two points of the gold surface. An enhancement of up to 8 times 
is observed per Gd unit (comparing unattached 8 to NP6 at 10 MHz and 37 °C) and the overall 
assembly displays r1 values of up to 5691 mM−
1 s−1 per nanoparticle (NP1). In contrast to 
monometallic (e.g. Dotarem™) or Gd units immobilised on nanoparticles or polymers where 
internal rotation is possible, an increase in temperature (as observed between 25 and 37 °C) 
results in an increase in r1 values and this is attributed to the combination of the rigidity in our 
system and the improved water exchange rate at elevated temperatures. Compared to our 
previous design,44 the fully functionalised assembly (NP10) displays better relaxivity both per 
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Gd and overall (particularly at 63.87 MHz, 1.5 T clinical field), despite more flexibility in the 
tether. Any loss of relaxivity from lower rigidity appears to be counteracted by more efficient 
packing, leading to a better loading of surface units. 
Since tumours often express only a few receptors, the targeting of these receptors with 
a huge payload of Gd units will help locate diseased tissue through a vastly improved MRI 
signal. The accumulation of gold nanoparticles in tumours (EPR effect) is enhanced by the 
inclusion of a unit capable of actively targeting folate receptors, which are overexpressed by 
HeLa cells. It appears that the combination of thioglucose and folic acid (FA-SH) units leads 
to a slight increase in cellular uptake in HeLa cells compared to a cell line (MCF-7) where the 
folate receptor is expressed less.96,97 
The nanomaterials prepared in this study are stable over a wide range of pH, salt 
concentrations (NaCl) and towards transmetallation (with Zn2+ ions) of the Gd surface units. 
They are all non-toxic, even at concentrations similar to those used clinically (250 M), 
however, on irradiation with light, the nanoparticles functionalised with the novel ZnTPP unit 
(15) display the ability to kill 75% of HeLa cells in 30 minutes. This provides a proof of 
principle for these materials being used both to evaluate disease progression and also deliver a 
photo-switchable and localised therapeutic intervention.98 The work described here has 
provided a new methodology for functionalising nanoparticles, which have the potential to 
deliver targeted (and hence lower dose) imaging/therapeutic agents. In any future clinical 
translation of such materials, the ability to image the localisation of the contrast agent and then 
apply light-driven therapy would represent a key advance in limiting the side effects associated 
with traditional chemotherapy drugs. In particular, the ability to only ‘switch on’ the cytotoxic 
effect (through the skin or via endoscope) when needed would allow targeting of the therapy 
and less collateral damage. 
 
Methods 
Materials and Equipment 
All chemicals and solvents were purchased from Alfa-Aesar, Sigma-Aldrich and VWR and 
were used without further purification, unless otherwise stated. All experiments and 
manipulations of compounds were conducted in air, unless otherwise specified. Solvent 
mixtures are volume/volume mixtures. A Waters LCT Premier ES-ToF (ESI) spectrometer was 
used for electrospray and high-resolution mass spectra (accurate mass mode). Standard FTIR 
spectra were measured using a Perkin Elmer Spectrum GX spectrometer. UV-Vis spectra were 
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recorded with a Perkin Elmer Lambda-20 spectrophotometer. Fluorescence measurements in 
solution were carried out using an Agilent (Varian) Cary Eclipse spectrofluorimeter. NMR 
spectroscopy was performed at 25 °C using a Bruker AV400 or 500MHz spectrometer at room 
temperature in CDCl3 unless otherwise stated. The widefield microscopy was carried out using 
a Zeiss Axio Observer inverted microscope. TEM images and EDS data were obtained using a 
JEOL 2010 high-resolution TEM (80-200 kV) equipped with an Oxford Instruments INCA 
EDS 80mm X-Max detector system. Thermogravimetric analysis was performed on a Mettler 
Toledo DSC 1LF/UMX Thermogravimetric Analyser. ICP-OES analyses were performed 
using a Perkin-Elmer OPTIMA 2000 DV ICP-OES spectrometer. Zeta-potential & DLS 
analyses were carried out on a Zetasizer Nano ZS90 DLS system (Malvern Instrument Ltd, 
England). NMRD profiles were recorded using a SMARtracer™ 0.25 T bench-top fast field 
cycling NMR relaxometer (Stelar). 
 
Synthesis of functionalised nanoparticles 
In a flask pre-washed with aqua regia and thoroughly rinsed with ultrapure water was 
introduced HAuCl4 (59 mg, 0.150 mmol, 1 eq.) in methanol (13 mL). The sulfur-based ligands 
(PEG-SH, thioglucose, 9, 15) were then introduced at the desired quantities (0.01 - 1 eq. relative 
to Au) in solution (ultrapure water for PEG-SH and thioglucose, a 1:1 mixture of methanol and 
acetonitrile for ZnTPP (15) and a 1:1 mixture of ultrapure water and DMSO for compound 8. 
The mixture was then cooled down to 4 °C with an ice bath for at least 10 minutes. A fresh 
solution of sodium borohydride (47.3 mg, 1.252 mmol, 8.4 eq.) in 3.3 mL of ultrapure water 
was then added dropwise. The mixture was stirred at 10 °C for 3 hours. The nanoparticles were 
then centrifuged at 5000 rpm for 45 minutes. The supernatant was removed and the 
nanoparticles were re-dispersed in water and re-centrifuged several times to ensure complete 
removal of any unattached surface units. Complete removal of unbound Gd chelates was 
confirmed by testing the relaxivity of the supernatant. 
 
Protocol for Relaxometry 
The NMRD profiles were measured at 1H Larmor frequencies from 0.01 to 10 MHz using a 
Stelar SMARtracer™ FFC NMR relaxometer (0.25 T), equipped with a VTC90 temperature 
control unit. Each point was measured 8 times and if the deviation was outside 1%, the 
measurement was repeated and the average value was taken. The measurements were made at 
25 °C and 37 °C for each gold nanoparticle (GNP) and the precise concentration of Gd3+ was 
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determined using ICP-OES. The r1 values were calculated by first subtracting the R1 of pure 
water from the R1 measured and then dividing the resulting value by the concentration of Gd
3+. 
 
Protocol for Magnetic Resonance Imaging 
Magnetic resonance imaging was performed at 25 °C on a clinical 1.5 T MRI Scanner (Philips 
Ingenia, Philips Medical Systems) using a Modified Look-Locker Imaging (MOLLI) T1 
sequence. The scan parameters were as follows: 15 x 300 x 300 mm field of view, 300 x 300 
mm acquisition matrix, 3 mm slice thickness, 2.145 ms echo time, 4.290 ms repetition time 
and 50° flip angle. Each nanoparticle sample was prepared at gadolinium concentrations (ICP-
OES) between 0.01 and 0.065 mM. The 1 mL phantoms were submerged in water during 
acquisition to reduce Gibbs artefacts. The T1 maps were analysed using Philips DICOM Viewer 
3.0. T1 values were extracted for each nanoparticle sample across 5 slices and a mean average 
value was taken. R1 was then plotted against gadolinium concentration and the gradient of the 
straight line was taken to be the relaxivity. 
 
Protocol for in vitro Viability Assay 
Cells were seeded into a 96-well plate at a density of 15,000 cells per well and incubated for 
24 h at 37 °C in a 5% CO2 incubator. The cells were then incubated with fresh media containing 
various concentrations of nanoparticle (0-250 µM) and incubated for a further 24 hours. The 
media was then replaced with a solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) in PBS (2 mg mL−1) and incubated for 2 hours. The 
solution was then replaced with DMSO to dissolve the formazan crystals and the absorbance 
at 570nm was measured using a 96-well plate reader (SpectraMax M2/M2e Microplate Reader 
from Molecular Devices). All experiments were repeated five times and the cell viability was 
reported as a percentage relative to the control cells. Error bars represent the standard deviation. 
 
Protocol for in vitro Uptake Study 
Cells were seeded into a 96-well plate at a density of 15,000 cells per well and incubated for 
24 h at 37 °C in a 5% CO2 incubator. The cells were then incubated with a 200 µM solution of 
the respective nanoparticle for a period of 1, 6 or 24 hours and in duplicates. The media was 
then removed and the cells were washed three times with PBS to ensure that all un-internalised 
nanoparticles had been removed. The cells were then fixed using a 4% formaldehyde solution 
and digested using aqua regia for at least 2 hours at room temperature. The digested solutions 
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were then diluted with water to reach a 10% concentration of aqua regia and the gold 
concentration was measured using ICP-OES. 
 
Protocol for in vitro Photodynamic Therapy Study 
HeLa cells were seeded into 8-well plates at a density of 30,000 cells per well and incubated 
for 24 h at 37 °C, in 5% CO2. The cells were then incubated with a 200 µM solution of the 
respective nanoparticle in media for a further 24 h. The media was then removed and the cells 
were washed 3 times with PBS before fresh media were added. Each well was then irradiated 
with a 570 nm laser, at 37 °C on a Zeiss-Axio Observer inverted microscope for a period of 5, 




The synthesis and characterisation of the surface units and functionalised nanoparticles are 
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S1. General considerations regarding starting materials and equipment 
 
All chemicals and solvents were purchased from Alfa-Aesar, Sigma-Aldrich and VWR and were used 
without further purification, unless otherwise stated. All experiments and manipulations of compounds 
were conducted in air, unless otherwise specified. Solvent mixtures are volume/volume mixtures. A 
Waters LCT Premier ES-ToF (ESI) spectrometer was used for electrospray and high-resolution mass 
spectra (accurate mass mode). Standard FTIR spectra were measured using a Perkin Elmer Spectrum 
GX spectrometer. UV-Vis spectra were recorded with a Perkin Elmer Lambda-20 spectrophotometer. 
Fluorescence measurements in solution were carried out using an Agilent (Varian) Cary Eclipse 
spectrofluorimeter. NMR spectroscopy was performed at 25 °C using Bruker AV400 or 500MHz 
spectrometers at room temperature in CDCl3 unless otherwise stated. 1H NMR and 13C NMR chemical 
shifts (δ) were referenced to the residual non-deuterated solvent signal and the 13C signal of the 
deuterated solvent, respectively. The deuterated solvents were all purchased from Sigma Aldrich. The 
widefield microscopy was carried out using a Zeiss Axio Observer inverted microscope in the Facility 
for Imaging by Light Microscopy (FILM). TEM images and EDS data were obtained at Imperial 
College using a JEOL 2010 high-resolution TEM (80-200 kV) equipped with an Oxford Instruments 
INCA EDS 80mm X-Max detector system. Thermogravimetric analysis was performed on a Mettler 
Toledo DSC 1LF/UMX Thermogravimetric Analyzer, using a ceramic sample holder. The protocol 
used was to heat between 30-120 °C at 30 °C per minute then hold at 120 °C for 20 minutes before 
continuing to heat between 120-600 °C at 10 °C per minute. ICP-OES analyses were performed using 
a Perkin-Elmer OPTIMA 2000 DV ICP-OES spectrometer. Zeta-potential & DLS analyses were carried 
on a Zetasizer Nano ZS90 DLS system (Malvern Instrument Ltd, England). NMRD profiles were 
recorded using a SMARtracer 0.25 T bench-top fast field cycling NMR relaxometer (King’s College 










Synthesis of DO3A-tri-tBu-ester·HBr (1·HBr)1 
 
At -20 °C, a suspension of cyclen (5.00 g, 29.02 mmol, 1.0 eq.) and sodium acetate (7.86 g, 95.82 mmol, 
3.3 eq.) in N,N-dimethylacetamide (DMA, 60 mL) was treated with a solution of tert-butyl 
bromoacetate (14.10 mL, 95.49 mmol, 3.3 eq.) in DMA (20 mL) dropwise over a period of 40 minutes. 
The temperature was maintained at -20 °C during the addition, then the mixture was stirred at room 
temperature for 24 hours. The reaction mixture was then poured onto water (300 mL) to afford a 
colorless solution. Sodium bicarbonate (12.60 g, 149.98 mmol, 5.1 eq.) was added in portions, inducing 
the precipitation of 1·HBr as a white solid. The precipitate was then filtered and dissolved in chloroform 
(250 mL). The solution was washed with water (100 mL), dried over sodium sulfate, filtered and 
concentrated to around 20-30 mL. Addition of diethyl ether (250 mL) led to precipitation of 1·HBr as 
a white solid (Yield: 13.50 g, 78%). 
 
1H NMR (400 MHz, DMSO-d6) δ 8.95 (broad, 2H, NH·HBr), 3.42 (s, 4H, NCH2COO), 3.35 (s, 2H, 
NCH2COO), 2.95 (m, 4H, NCH2CH2N), 2.85 (m, 4H, NCH2CH2N), 2.70 (m, 8H, NCH2CH2N), 1.42 (s, 
18H, CH3), 1.41 (s, 9H, CH3) ppm. 
13C{1H} NMR (101 MHz, DMSO-d6) δ 170.6, 169.9 (COO), 80.5, 80.5 (C(CH3)), 56.1, 51.8, 50.6, 49.7, 
48.3, 45.6 (NCH2CH2N, NCH2COO), 27.8 (C(CH3)3) ppm. 
MS (ES-Positive) for C26H51N4O6: calculated [M]+ 515.3808, found [M]+ 515.3793. 
 
 
Synthesis of 2-bromo-5-methoxy-5-oxopentanoic acid (2)2 
 
L-Glutamic acid 5-methyl ester (2.00 g, 12.41 mmol, 1.0 eq.) and sodium bromide (4.34 g, 42.19 mmol, 
3.4 eq.) were dissolved in a 2N aqueous solution (15 mL) of hydrobromic acid (22.08 mmol, 1.8 eq) 
and cooled to 0 °C. Sodium nitrite (1.52 g, 22.08 mmol, 1.8 eq.) was added in portions. After stirring 
for 2 hours, conc. sulfuric acid (0.75 ml) was added followed by 15 minutes of stirring at room 
4 
 
temperature. The aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined organic 
phases were dried over magnesium sulfate and concentrated to afford a white powder (2.06 g, 73%). 
 
1H NMR (400 MHz, CDCl3) δ 9.86 (s, 1H, COOH), 4.37 (dd, J = 8.5, 5.7 Hz, 1H, BrCHCOOH), 3.67 
(s, 3H, OCH3), 2.58 – 2.50 (m, 2H, CH2CH2), 2.44 – 2.19 (m, 2H, CH2CH2) ppm. 
13C{1H} NMR (101 MHz, CDCl3) δ 174.1, 172.9 (COO), 52.1 (OCH3), 44.3 (BrCH), 31.3, 29.5 
(CH2CH2) ppm.  
MS (ES-Positive) for C6H9BrO4: calculated [M+H]+ 224.9762, found [M+H]+ 224.9779. 
 
 
Synthesis of 1-tert-butyl 5-methyl 2-bromopentanedioate (3)2 
 
Compound 2 (2.06 g, 9.10 mmol, 1.0 eq.), DCC (2.44 g, 11.83 mmol, 1.3 eq.) and 4-
dimethylaminopyridine (DMAP) (0.11 g, 0.91 mmol, 0.1 eq.) were dissolved in anhydrous 
dichloromethane (10 mL). The solution was cooled to 0 °C and t-butanol (4.00 mL, 36.40 mmol, 4.0 
eq.) was added. The solution was then stirred overnight at room temperature. The precipitate was 
filtered and the filtrate was concentrated under vacuum. The residue was dissolved in dichloromethane 
and washed with a 0.5N HCl solution followed by a saturated aqueous solution of sodium bicarbonate. 
The organic layer was dried over magnesium sulfate, filtered and dried under vacuum to yield a yellow 
oil which was purified by column chromatography on silica gel 60 (40-63 µm) (eluent 1:1 v/v ethyl 
acetate/hexane, Rf: 0.70) (Yield: 1.44g, 76%). 
 
1H NMR (400 MHz, CDCl3) δ 4.21 (dd, J = 8.5, 5.9 Hz, 1H, BrCHCOOH), 3.66 (s, 3H, OCH3), 2.48 
(m, 2H, CH2CH2), 2.36 – 2.15 (m, 2H, CH2CH2), 1.45 (s, 9H, C(CH3)3) ppm. 
13C{1H} NMR (101 MHz, CDCl3) δ 172.65 (COOMe), 168.37 (COOtBu), 82.69 (C(CH3)3), 51.89 
(OCH3), 46.76 (BrCH), 31.45, 29.82, (CH2CH2), 27.81 (C(CH3)3) ppm.  
MS (CI-Positive) for C10H17BrO4: calculated [M+NH4]+ 298.0654, found [M+NH4]+ 298.0647. 
 
 
Synthesis of DO3A- tert-butylester-4-methylesterpentane (4) 
 
The compound 1·HBr (3.40 g, 5.70 mmol, 1.0 eq.) was dissolved in anhydrous acetonitrile (200 mL). 
Potassium carbonate (3.15 g, 22.80 mmol, 4.0 eq.) was added to the reaction mixture which was then 
heated at reflux for 30 minutes. Compound 3 (1.23 g, 5.94 mmol, 1.1 eq.) was then added and the 
mixture was left to stir at 70 °C for 24 hours. The unreacted potassium carbonate was removed by 
filtration and the solvent was removed under vacuum affording a yellow oil. The product was purified 
by column chromatography on silica gel (eluent 96:4 v/v dichloromethane/ methanol, Rf: 0.58) giving 
a yellow solid after evaporation of the solvent. (Yield: 4.10 g). 
 
1H NMR (400 MHz, CDCl3) δ 3.63 (s, 3H, OCH3), 3.48 (d, J=10.4 Hz, 1H, NCHCOO), 3.42 – 3.31 (m, 
4H, NCH2CH2N), 3.26-2.99 (m, 4H, NCH2CH2N), 2.88-2.72 (m, 4H, NCH2CH2N), 2.63-2.42 (m, 6H, 
NCH2COO), 2.38-2.23 (m, 4H, NCH2CH2N), 2.19-2.07 (m, 2H, CH2CH2COO), 2.03-1.92 (m, 1H, 
CHCH2CH2), 1.75-1.63 (m, 1H, CHCH2CH2), 1.49-1.36 (m, 36H, C(CH3)3) ppm. 
13C{1H} NMR (101 MHz, CDCl3) δ 174.8 (CH2COOCH3), 173.5, 173.1, 173.0 (CH2COO), 82.6, 82.0, 
81.9 (C(CH3)3), 60.0 (NCHCOO), 56.0, 55.9, 55.7, 52.8, 52.6, 51.7, 48.7, 48.3, 47.4, 44.5, 32.4 
(NCH2CH2N, NCH2COO), 28.0, 27.9, 27.9 (C(CH3)3), 19.5 (CHCH2CH2) ppm. 
MS (ES-Positive) for C36H66N4O10: calculated [M + H]+ 715.4857, found [M + H]+ 715.4849. 
IR (solid state, cm-1) 2985, 2937, 2862 [ν(C-H)], 1725 [ν (C=O)], 1371 [ν (C-H)], 1225 [ν (C=O) ester], 
1160, 1108 [ν(C-N)]. 
Anal. Calcd (%) C36H66N4O10·2CH2Cl2·2H2O: C 49.6, H 8.1, N 6.1; Found: C 49.0, H 7.7, N 6.5. 
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Synthesis of DO3A- 4-tertiobutylesterbutanoic acid (5)3 
 
Compound 4 (4.10 g, 5.75 mmol, 1.0 eq.) and NaOH (0.47 g, 11.50 mmol, 2.0 eq.) were dissolved in 
methanol (20 mL) and stirred at 50 °C overnight. The solution was neutralized to pH 7 with a 1M 
aqueous HCl solution. The solvent was removed under vacuum and the residue was dissolved in 
dichloromethane, washed with water and brine, dried over sodium sulfate, filtered and all solvent 
removed under vacuum to afford a yellow oil. (Yield: 3.20 g, 81%). 
 
1H NMR (400 MHz, 223K, CDCl3) δ 3.50 (d, J = 10.0 Hz, 1H, NCHCOO), 3.47–3.28 (m, 4H, 
NCH2CH2N), 2.99–2.74 (m, 8H, NCH2CH2N), 2.72–2.47 (m, 6H, NCH2COO) 2.32–2.20 (m, 4H, 
NCH2CH2N), 2.16–2.07 (m, 2H, CH2CH2COOH), 2.05–1.96 (m, 1H, CHCH2CH2), 1.70–1.60 (m, 1H, 
CHCH2CH2), 1.46–1.38 (m, 36H, C(CH3)3) ppm. 
13C{1H} NMR (101 MHz, 223K, CDCl3) δ 175.2 (CH2COOH), 172.7, 172.6, 172.3, 172.2 (CH2COO), 
82.2, 82.1, 81.9, 81.8 (C(CH3)3), 59.2 (NCHCOO), 55.4, 55.3, 55.1 52.4, 52.3, 48.1, 48.0, 47.6, 46.7, 
43.8, 33.3 (NCH2CH2N, NCH2COO), 27.8, 27.7, 27.6 (C(CH3)3), 20.3 (CHCH2CH2) ppm. 
MS (ES-Positive) for C35H64N4O10: calculated [M + H]+ 701.4701, found [M + H]+ 701.4686. 
 
 
Synthesis of DOTA-boc-piperazine-tetra-tBu-ester (6) 
 
Compound 5 (1.10 g, 1.57 mmol, 1.0 eq.) and N-hydroxysuccinimide (NHS) (0.40 g, 3.45 mmol, 2.2 
eq.) were dissolved in anhydrous dichloromethane (25 mL). The mixture was then cooled to 0 °C, after 
which N,N-dicyclohexylcarbodiimide (DCC) (0.39 mg, 1.88 mmol, 1.2 eq.) was added. The reaction 
mixture was left to stir at 0 °C for 3 hours. 1-boc-piperazine (0.31 g, 1.73 mmol, 1.1 eq.) was dissolved 
in anhydrous dichloromethane (15 mL) and added at 0 °C. The reaction was left to stir for another 2 
hours at 0 °C after which it was stirred for 18 hours at room temperature. The precipitate was filtered 
and the filtrate was then evaporated to dryness. The foamy solid obtained was dissolved in acetonitrile 
(10 mL) and kept at -20 °C for 2 hours, producing a precipitate. After filtration, the filtrate was 
evaporated and dissolved in dichloromethane (20 mL) and washed with an aqueous solution of 2 M 
NaOH (2 x 10 mL). The organic phase was dried over Na2SO4, filtered and evaporated to dryness to 
afford a yellow foam which was purified by purified by column chromatography on silica gel (eluent 
90:10 v/v dichloromethane/ methanol, Rf: 0.47) (Yield: 1.20 g, 88%). 
 
IR (solid state, cm-1): 2980, 2938, 2865 (νC-H), 1724, 1701 (νC-O), 1646 (νC=O), 1368 (νC-H), 1228 (νC=O), 
1157, 1107 (νC-N). 
1H NMR (400 MHz, CDCl3) δ 3.48–3.33 (m, 4H, CH2CH2), 3.27–2.53 (m, 29H, NCH2CH2N, 
NCH2COO), 1.89–1.83 (m, 1H, NCHCOO), 1.48–1.44 (m, 45H, C(CH3)3) ppm. 
13C{1H} NMR (101 MHz, CDCl3) δ 175.2 ,173.0, 172.9, 172.8, 170.7 (CH2COO), 154.6 (NCOO), 82.4, 
82.1, 82.0, 81.9, 80.5 (C(CH3)3), 59.7 (NCHCOO), 56.0, 55.9, 55.6, 52.7, 52.6, 48.6, 48.2, 47.3, 45.2, 
44.4, 41.4, 31.0 (NCH2CH2N, NCH2COO), 28.4, 28.70, 27.9, 27.8 (C(CH3)3), 19.8 (CHCH2CH2) ppm. 
MS (ES-Positive) for C44H80N6O11: Calculated [M + H]+ 869.5963, found [M + H]+ 869.5942. 
 
 
Synthesis of DOTAGA-piperazine TFA (7) 
 
Compound 6 (1.20 g, 1.38 mmol, 1.0 eq.) was dissolved in a 1:3 v/v ratio mixture of trifluoroacetic acid 
and dichloromethane stirred at room temperature for 48 hours. All solvent was removed under vacuum 
and the residue was then dissolved in dichloromethane and the solvent evaporated again. This process 
was performed 3 times with dichloromethane and 3 times with methanol. The oily residue was dissolved 
in a minimum of methanol and diethyl ether was added to induce precipitation of the product. After 
trituration of the solid, the solvent was isolated as a colorless powder (Yield: 0.91 g, 99%). 
6 
 
IR (solid state, cm-1) 3464, 3106 [ν(O-H)], 2930, 2857 [ν(C-H)], 1676 [ν (C=O) ester], 1629 [ν (C=O) 
amide], 1391 [ν (C-H)], 1200 [ν (C=O) ester], 1177, 1122 [ν (C-N)]. 
1H NMR (400 MHz, D2O) δ 4.01-3.93 (m, 1H), 3.90–3.74 (m, 13H) 3.71–3.53 (m, 3H), 3.47–3.22(m, 
8H), 3.19–2.95 (m, 3H), 2.87–2.75 (m, 1H), 2.66–2.47 (m, 1H), 2.02–1.84 (m, 2H), 1.51–1.40 (m, 1H) 
ppm. 
13C{1H} NMR (101 MHz, D2O) δ 175.1, 173.6, 173.5, 172.6, 171.2 (CH2COO), 163.1, 162.8 (NCOO), 
117.8, 114.9 (TFA salt), 56.0, 53.5, 51.1, 50.4, 48.4, 45.4, 43.1, 43.0, 42.9, 42.5, 40.3, 38.5, 33.0 
(NCHCOO,NCH2CH2N, NCH2COO,CHCH2CH2) ppm. 
MS (ES-Positive) for C23H41N6O9: calculated [M]+ 545.2935, found [M]+ 545.2941. 
Anal. Calcd (%) for C23H41N6O9·0.8Et2O·H2O: C 40.1, H 6.1, N 9.3; Found: C 40.4, H 5.6, N 9.7. 
 
 
Synthesis of [Gd(DOTAGA-piperazine)] (8) 
 
Compound 7 (0.81 g, 1.23 mmol, 1 eq.) was dissolved in water (10 mL) and GdCl3·6H2O (0.55 g, 1.48 
mmol, 1.2 eq.) was added. The pH of the solution was adjusted to 5.6 by addition of an aqueous solution 
of NaOH. The reaction mixture was stirred at room temperature and the pH was monitored and adjusted 
to 5.5-6.0. Once the pH was stable, the reaction was stirred overnight at 50 °C. The mixture was then 
cooled to room temperature, after which the pH was adjusted to 10.9 and stirred for 40 minutes in order 
to precipitate Gd(OH)3. The reaction mixture was then centrifuged, the supernatant was collected and 
its pH adjusted to 6.5. The xylenol orange test was performed in order to detect any uncomplexed 
gadolinium. If the test detected the presence of uncomplexed gadolinium, the workup procedure was 
repeated until no free gadolinium could be detected (Yield: 0.98 g, 98%). 
 
IR (solid state, cm-1) 3451, 3155 [ν(O-H)], 2934, 2864 [ν(C-H)], 1676 [ν (C=O) ester], 1614 [ν (C=O) 
amide], 1404 [ν (C-H)], 1205 [ν (C=O) ester], 1130, 1090 [ν (C-N)]. 
MS (ES-Positive) for C23H38N6O9Gd: calculated [M + H]+ 700.1941, found [M + H]+ 700.1939. 
 
 
Figure S2-1 NMRD relaxivity profiles of compound 8 at 25 and 37 °C. 
 
As a control to confirm the reaction of carbon disulfide to form the dithiocarbamate needed for 
attachment to the gold surface, attempts were made to prepare AuNPs with just 8. In contrast to the 
color change to orange observed with dithiocarbamate 9, addition of 8 (ammonium salt) to HAuCl4 led 
to no color change indicating that no reaction had taken place. Continuing with the protocol to form the 
nanoparticles, addition of the reducing agent NaBH4 led instead to immediate aggregation and 
precipitation of an insoluble solid (in water, MeOH). This behavior occurs on formation of colloidal 
























Figure S2-2 Relaxivity measurements for compound 8 in PBS on addition of 10 eq. Zn(OAc)2 at 37 °C 
indicating stability to transmetallation and loss of gadolinium(III) ions. 
 
Figure S2-3 Relaxation rate temperature dependance of 8 indicating a decrease in relaxivity with 
increasing temperature.  
 
 
































































Figure S2-5 MTT cell viability assays for compound 8. 
 
 
Synthesis of Gd(DOTAGA-piperazine-dithiocarbamate) dipotassium salt (9) 
 
A solution of 8 (50 mg, 0.076 mmol, 1 eq.) in 5 mL of dry methanol was treated with potassium 
carbonate (84 mg, 0.608 mmol, 8 eq.) under nitrogen. The mixture was stirred for 1 hour at room 
temperature. Carbon disulfide (4.6 µL, 0.076 mmol, 1.2 eq.) was then added at room temperature and 
the mixture was stirred for another hour. The mixture was filtered through Celite and the filtrate directly 
used for the functionalization of gold nanoparticles, assuming a quantitative yield. 
 
IR (solid state, cm-1) 3397 [ν(O-H)], 2979 [ν(C-H)], 1676 [ν(C=O) ester], 1601 [ν(C=O) amide], 1427 
[ν(C-N)], 1203 [ν(C=O) ester], 1129 [ν(C-N)], 1002 [ν(C-S)]. 
MS (ES-Positive) for C24H35N6O9S2Gd: calculated [M + K]+ 812.0785, found [M + K]+ 812.1283. 
 
 
Synthesis of [Eu(DOTAGA-piperazine)] (10) 
 
Compound 7 (50 mg, 0.076 mmol, 1 eq.) was dissolved in water (10 mL) and EuCl3·6H2O (34 mg, 
0.091 mmol, 1.2 eq.) was added. The pH of the solution was adjusted to 5.6 by addition of an aqueous 
solution of NaOH. The reaction mixture was stirred at room temperature and the pH was monitored and 
adjusted to 5.5-6. Once the pH was stable, the reaction was stirred overnight at 50 °C. The mixture was 
then cooled to room temperature, after which the pH was adjusted to 10.9 and stirred for 40 minutes in 
order to precipitate Eu(OH)3. The reaction mixture was then centrifuged, the supernatant was collected 
and its pH adjusted to 6.5. The mixture was purified by size exclusion column (Sephadex G-10). 
 
13C{1H} NMR (101 MHz, D2O) δ 209.5 (CS2), 180.0 (NCHCOO), 168.0 (NCH2COO), 162.8 (NCO), 
50.7 (CS2NCH2), 44.9 (CS2NCH2CH2), 32.0 (NCHCOO, NCH2CH2N, NCH2COO, CHCH2CH2) ppm. 








































Figure S2-6 Absorption spectrum of 10. 
 
 
Figure S2-7 Emission spectrum of 10. 
 
 
Figure S2-8 Lifetime measurement of 10 in H2O and D2O (pH 7.5, 298K). 
 
 
Table S2-1 Summary of results of the Lifetime measurment of 10 and hydration number 
 
  λex/λem (nm) KH2O (ms-1) τ (ms) KD2O (ms-1) τ (ms) q 
Compound 10 230/690 1.37938645 0.72496 0.37829781 2.64342 0.901306 
 
















































Synthesis of FA-SH (11)4 
 
A solution of folic acid (200 mg, 0.453 mmol, 1 eq.) in dry dimethylsulfoxide (10 mL) was initially 
heated under nitrogen at 50 °C to ensure complete dissolution of the starting material. After cooling to 
room temperature, N-hydroxysuccinimide (NHS) (104 mg, 0.906 mmol, 2 eq.), 4-
(dimethylamino)pyridine (DMAP) (11 mg, 0.091 mmol, 0.2 eq.) and N,N'-dicyclohexylcarbodiimide 
(DCC) (103 mg, 0.498 mmol, 1.1 eq.) were added. The mixture was stirred at room temperature for 3 
hours before addition of 4-aminothiophenol (47 µL, 0.453 mmol, 1 eq.). The mixture was stirred 
overnight under nitrogen. After filtration through Celite, the filtrate was poured onto a cold 1:3 mixture 
of acetone and diethyl ether. The precipitate was filtered and washed with dichloromethane, acetone 
and diethyl ether to give 11 as an orange oily solid (Yield: 250 mg, 99%). 
 
NMR data compared well with those reported in the literature.4 
MS (ES-Positive) for C25H24N8O5S: calculated [M + H]+ 549.1669, found [M + H]+ 549.1647. 









Synthesis of meso-tetraphenylporphyrin (12)5 
 
Freshly distilled pyrrole (5.60 ml, 80 mmol) and benzaldehyde (8 mL, 80 mmol) were added to 
propionic acid (300 mL) and heated at reflux for 30 min. The solution was then cooled to room 
temperature and filtered, the filtered solid was washed thoroughly with methanol. After a hot water 
wash, the resulting purple crystals were air dried, and finally dried under vacuum to give the purple 
product (Yield: 2.50 g, 5%). 
 
1H NMR (400 MHz, CDCl3) δ 8.90 (s, 8H, pyrrole), 8.27 (m, 8H, ortho-phenyl), 7.80 (m, 12H, 
para/meta-phenyl), -2.72 (s, 2H, NH) ppm. 
 
 
Synthesis of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (13)6 
 
A solution of 12 (500 mg, 0.81 mmol) in trifluoroacetic acid (40 mL) was treated with sodium nitrite 
(100 mg, 1.45 mmol). After 55 min stirring at room temperature, the reaction was quenched with water 
(250 mL) and the mixture extracted with dichloromethane. The organic layers were washed once with 
saturated aqueous NaHCO3 and once with water before being dried over anhydrous Na2SO4. The solvent 
was removed under vacuum and the residue was dissolved in 40 mL of concentrated hydrochloric acid 
and heated to 65 °C. After 10 min of stirring at 65 °C tin(II) chloride (1.18g, 5.23 mmol) was added. 
The mixture was stirred for 1 hour at 65 °C, after which it was poured in 250 mL of water and cooled 
to room temperature. The solution was adjusted to pH 8 using ammonium hydroxide. The solution was 
then extracted with dichloromethane, dried over Na2SO4 and the solvent was removed under vacuum. 
The product was purified by column chromatography on silica gel (eluent dichloromethane) giving a 
purple solid after evaporation of the solvent (Yield: 251 mg, 49%). 
12 
 
1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 4.8 Hz 2H, pyrrole), 8.86 (s, 6H, pyrrole), 8.24 (m, 6H, 
ortho-phenyl), 8.02 (m, 2H, ortho-aminophenyl), 7.78 (m, 9H, para/meta-phenyl), 7.07 (m, 2H, meta-
aminophenyl), 4.06 (s, 2H, NH2), -2.74 (s, 2H) ppm. 
 
 
Synthesis of Porph-lipoic acid 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (14) 
 
Compound 13 (111 mg, 0.17 mmol) and lipoic acid (40 mg, 0.19 mmol) were dissolved in anhydrous 
DMF followed by addition of HOBt (26 mg, 0.19 mmol), DMAP (2 mg, 0.018 mmol), EDCl (37 mg, 
0.19 mmol) and Et3N (26 µl, 0.19 mmol). The reaction was stirred at room temperature for 48 hours 
followed by addition of H2O (15 mL) and EtOAc was then used to extract the product. The organic 
phase was washed with water and then dried over Na2SO4. The product was purified by column 
chromatography on silica gel (eluent dichloromethane) giving a purple solid after evaporation of the 
solvent (Yield: 113 mg, 80%). 
 
IR (solid state, cm-1): 3376, 3321, 3054, 3026, 2930, 2857, 2611, 2535, 1698,1669, 1594, 1517, 1474, 
1442, 1402, 1350, 1306, 1181, 1128, 1072, 981, 966, 798, 723, 699, 658, 572, 560, 522, 513. 
1H NMR (400 MHz, CDCl3) δ 8.86 (s, 8H, pyrrole), 8.25-8.19 (m, 6H, ortho-phenyl), 8.18-8.11(m, 2H, 
ortho-aminophenyl), 7.89-7.82 (m, 1H, meta-aminophenyl), 7.82-7.70 (m, 10H, meta-phenyl, meta-
aminophenyl), 7.41(s, 1H, NH), 4.25-4.08 (m, 1H, CH), 3.64-3.49 (m, 1H), 3.48-3.32 (m, 1H), 2.70-
2.56 (m, 1H), 2.53-2.45 (m, 1H), 2.44-2.37(m, 1H), 2.33-2.07 (m, 1H), 1.95-1.44 (m, 5H), -2.75 (s, 2H) 
ppm. 
13C{1H} NMR (101 MHz, CDCl3) δ 171.0 (CO), 142.2 (Arq), 137.6 (ArqNH), 135.2, 134.7 (Ar), 131.3 
(pyrrole), 127.9, 126.8 (Ar), 120.3 (Arq), 118.1, 118.0 (ArNH), 59.7 (COCH2), 55.4 (CH), 37.2, 36.3, 
30.8, 27.8, 26.5 (CH2) ppm. 
MS (ES-Positive) for C52H43N5OS2: Calculated [M + MeOH + H]+ 850.3250, found [M + MeOH + H]+ 
850.2937. 
Anal. Calcd (%) for C52H43N5OS2 1.5CH2Cl2: C 68.0, H 4.9, N 7.4; Found: C 67.8, H 5.0, N 7.6. 
 







Synthesis of Zn-Porph-lipoic acid (15) 
 
Compound 14 (20 mg, 0.024 mmol) was dissolved in dichloromethane and ZnOAc (11mg, 0.036 mmol) 
was dissolved in MeOH, added to the reaction mixture and stirred at room temperature for 8h. The 
solution was washed with water twice and dried over Na2SO4 and the solvent evaporated. The product 
was purified by column chromatography on silica gel (eluent dichloromethane) giving a purple solid 
after evaporation of the solvent. The product was recrystallized from a dichloromethane/hexane solution 
to produce a purple solid (17 mg, 80%). 
 
IR (solid state, cm-1): 3340, 3051, 2921, 2850, 1651, 1595, 1522, 1484, 1439, 1400, 1339, 1302, 1262, 
1203, 1179, 1124, 1068, 993, 795, 751, 717, 701, 660, 571, 501, 438. 
1H NMR (400 MHz, THF-d8) δ 9.50 (d, J = 12.3 Hz, 1H, NH), 8.91 (d, J = 4.6 Hz, 2H, pyrrole), 8.84 
(d, J = 4.4 Hz, 6H, pyrrole) 8.24-8.15 (m, 6H, ortho-phenyl), 8.13-8.08 (m, 2H, amino-phenyl), 8.08-
8.04 (m, 2H, amino-phenyl), 7.79-7.67 (m, 9H, meta, para-phenyl), 4.37-4.25 (m, 1H, CH), 3.69-3.55 
(m, 1H), 3.53-3.44 (m, 1H), 2.78-2.63 (m, 1H), 2.52-2.47 (m, 2H), 2.32-2.17 (m, 1H), 2.12-1.49 (m, 
6H) ppm. 
13C{1H} NMR (101 MHz, DMSO-d6) δ 171.5 (CO), 151.4, 151.3, 151.0, 150.9, 144.6, 140.3, 138.9, 
138.0 (Cq), 135.6 (amino-phenyl), 135.4 (ortho-phenyl), 132.3, 132.2 (pyrrole), 128.1, 127.2 
(meta/para-phenyl), 121.5 (amino-phenylq), 117.8 (amino-phenyl), 60.3 (CH2), 56.1 (CH), 37.4, 32.3, 
31.5, 28.8, 28.6, 27.5 (6 x CH2) ppm. 
MS (ES-Positive) for C52H41N5OS2Zn: calculated [M + H + MeCN + Na]+ 944.2285, found [M + H + 
MeCN + Na]+ 944.2006. 
Anal. Calcd (%) for C52H41N5OS2Zn CH2Cl2 2C4H8O: C 66.0, H 5.4, N 6.3; Found: C 65.9, H 5.5, N 
5.8. 
 




Figure S4-3 MTT viability assays for 15. 
 
 
S5. Synthesis of the functionalized gold nanoparticles (GNPs) 
 
General protocol for the synthesis of gold nanoparticles (adapted Brust-Schiffrin method):7  
 
In a flask pre-washed with aqua regia and thoroughly rinsed with ultrapure water was introduced 
HAuCl4 (59 mg, 0.150 mmol, 1 eq.) in methanol (13 mL). The sulfur-based ligand(s) (PEG-SH, 
thioglucose, 8, 15) were then introduced at the desired quantities (0.01 - 1 eq. relative to Au) in solution 
(ultrapure water for PEG-SH and thioglucose, in a 1:1 mixture of ultrapure water and DMSO for 8 and 
in a 1:1 mixture of methanol and acetonitrile for 15). The mixture was then cooled down to 4°C with 
an ice bath for at least 10 minutes. A fresh solution of sodium borohydride (47.3 mg, 1.252 mmol, 8.4 
eq.) in 3.3 mL of ultrapure water was then added dropwise. The mixture was stirred at 10 °C for 3 hours. 
The nanoparticles were then centrifuged at 5000 rpm for 45 minutes. The supernatant was removed and 
the nanoparticles were redispersed in water and centrifuged several times to ensure complete removal 







































S6. Characterization of the AuNPs 
 











S6.2 Characterization of NP1[Gd] 
 
               
      Figure S6.2-1 UV-vis spectrum of NP1           Figure S6.2-2 TEM image of NP1. 
 
 
Figure S6.2-3 Relaxivity data for NP1 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq. 
per Gd) in a transmetallation experiment at 37 °C. 
 
  








































































Figure S6.2-5 EDX data for NP1. 
 
 
Figure S6.2-6 UV-vis spectra of NP1 at various salt concentrations over time. 
 
 



























































Figure S6.2-8 UV-vis spectra of NP1 in DMEM at various time points. 
 
 
Figure S6.2-9 NMRD profiles of NP1 at 25 and 37 °C. 
 
 


















































Zeta Potential / mV − 36.5 
TEM diameter / nm 4.08 ± 0.67 
Hydrodynamic diameter / nm 11.59 ± 4.42 
20 
 
The composition of NP1 was calculated to be Au3301(C24H35GdN6O9S2)206 based on a combination of 
TEM data (diameter) to provide the number of Au atoms (assuming NP is a sphere) and TGA data to 
provide information on mass loss for the organic chelate. The number of gold atoms (N) is calculated 
from N = (Rcluster/Ratom)3 = (2.04 x 10-9/1.37 x 10-10)3. Number of Gd taken from the % mass loss from 
TGA data (16% mass loss due to the organic part of the ligand) with the remaining 84% made up of 
approximately 80.3% Au and 3.7% Gd. 
 
Table S6.2-2 Ratios of Au to Gd determined by ICP and TGA and overall relaxivity of NP1. 
Estimate of number of 




































S6.3 Characterization of NP2[Gd]/PEG (1/0.05) 
 
              
    Figure S6.3-1 UV-vis spectrum of NP2.            Figure S6.3-2 TEM image of NP2. 
 
 
Figure S6.3-3 Relaxivity data for NP2 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq per 
Gd) in a transmetallation experiment at 37 °C. 
 
  











































































Figure S6.3-5 EDX data for NP2. 
 
 
Figure S6.3-6 UV-vis spectra of NP2 at various salt concentrations over time. 
 
 


























































Figure S6.3-8 UV-vis spectra of NP2 in DMEM over time. 
 
 
Figure S6.3-9 NMRD profiles of NP2 at 25 and 37 °C. 
 
 





Table S6.3-2 Ratios of Au to Gd determined by ICP and overall relaxivity for NP2 
Estimated number of Gd per Au atoms Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 












































Zeta Potential / mV − 39.8 






















S6.4 Characterization of NP3[Gd]/PEG/TG (1:0.05:0.05) 
 
         
          Figure S6.4-1 UV-vis spectrum of NP3.        Figure S6.4-2 TEM image of NP3. 
 
 
Figure S6.4-3 Relaxivity for NP3 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq. per 
Gd) in a transmetallation experiment at 37 °C. 
 
 






































































Figure S6.4-5 EDX data for NP3. 
 
 
Figure S6.4-6 UV-vis spectra of NP3 at various salt concentrations over time. 
 
 


























































Figure S6.4-8 UV-vis spectra of NP3 in DMEM over time.  
 
 
Figure S6.4-9 NMRD profiles of NP3 at 25 and 37 °C. 
 
Table S6.4-1 Zeta-potential and size of NP1. 
Zeta potential / mV − 35.6 
TEM diameter / nm 3.72 ± 0.69 
 
Table S6.4-2 Ratios of Au to Gd determined by ICP and overall relaxivity for NP3 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 





































































S6.5 Characterization of NP4[Gd]/PEG/FA (1:0.05:0.01) 
 
                     
Figure S6.5-1 UV-vis spectrum of NP4.  Figure S6.5-2 TEM image of NP4. 
 
 
Figure S6.5-3 Relaxivity of NP4 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq per Gd) 
in a transmetallation experiment at 37 °C.  
 
 









































































Figure S6.5-5 EDX data for NP4. 
 
 
Figure S6.5-6 UV-vis spectra of NP4 at various salt concentrations over time. 
 
 


























































Figure S6.5-8 UV-vis spectra of NP4 in DMEM over time. 
 
 
Figure S6.5-9 NMRD profiles for NP4 at 25 and 37 °C. 
 
 
Table S6.5-1 Zeta potential and size of NP4. 
Zeta potential / mV − 39.0 
TEM diameter / nm 3.72 ± 0.73 
 
Table S6.5-2 Ratios of Au to Gd determined by ICP and overall relaxivity of NP4 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 


































































S6.6 Characterization of NP5[Gd]/PEG/TG/FA (1:0.05:0.05:0.01) 
 
   
      Figure S6.6-1 UV-vis spectrum of NP5.      Figure S6.6-2 TEM image of NP5. 
 
 
Figure S6.6-3 Relaxivity of NP5 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq. per 
Gd) in a transmetallation experiment at 37 °C. 
 
 







































































Figure S6.6-5 EDX data for NP5 
 
 
Figure S6.6-6 UV-vis spectra of NP5 at various salt concentrations over time. 
 
 


























































Figure S6.6-8 UV-vis spectra of NP5 in DMEM over time. 
 
 
Figure S6.6-9 NMRD profiles for NP5 at 25 and 37 °C. 
 
 
Table S6.6-1 Zeta potential, DLS and size of NP5. 
Zeta potential / mV − 37.1 
TEM diameter / nm 3.83 ± 0.59 



















































Figure S6.6-10 DLS data for NP5. 
 
Table S6.6-2 Ratios of Au to Gd determined by ICP and overall relaxivity of NP5. 
ICP data Ratio (Au/Gd) NP r1 (10 MHz) 























S6.7 Characterization of NP6[Gd]/Porph (1:0.5) 
 
     
                    Figure S6.7-1 UV-vis spectrum of NP6.             Figure S6.7-2 TEM image of NP6. 
 
 
Figure S6.7-3 Relaxivity between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq per Gd) in a 
transmetallation experiment at 37 °C for NP6. 
 
 











































































































































































Figure S6.7-9 NMRD profiles of NP6 at 25 and 37 °C. 
 
 
Table S6.7-1 Zeta potential and size of NP6. 
Zeta potential / mV − 33.1 
TEM diameter / nm 2.77 ± 0.49 
 
 
Table S6.7-2 Ratios of Au to Gd determined by ICP-OES and overall relaxivity of NP6 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 













































S6.8 Characterization of NP7[Gd]/PEG/Porph (1:0.05:0.5) 
 
                          
Figure S6.8-1 UV-vis spectrum of NP7.                  Figure S6.8-2 TEM image of NP7. 
 
 
Figure S6.8-3 Relaxivity for NP7 values between t = 0 to t = 2610 minutes on addition of Zn2+ (2 eq 
per Gd) in a transmetallation experiment at 37 °C. 
 
 































































































































































Figure S6.8-9 NMRD profiles of NP7 at 25 and 37 °C. 
 
 
Table S6.8-1 Zeta potential, DLS and size of NP7. 
Zeta potential / mV − 32.8 
TEM diameter / nm 2.62 ± 0.53 
Hydrodynamic diameter / nm 37.22 ± 5.92 
 
 
Table S6.8-2 Ratios of Au to Gd determined by ICP-OES and overall relaxivity of NP7. 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 


















































S6.9 Characterization of NP8[Gd]/PEG/FA/Porph (1:0.05:0.05:0.5) 
 
                  
    Figure S6.9-1 UV-vis spectrum of NP8.        Figure S6.9-2 TEM image of NP8. 
 
 
Figure S6.9-3 Relaxivity for NP8 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq per 
Gd) in a transmetallation experiment at 37 °C.  
 
 




































































Figure S6.9-5 EDX data for NP8. 
 
 























































































Figure S6.9-9 NMRD profiles of NP8 at 25 and 37 °C. 
 
 
Table S6.9-1 Zeta potential and size of NP8. 
Zeta potential / mV − 36.2 
TEM diameter / nm 2.93 ± 0.53 
 
 
Table S6.9-2 Ratios of Au to Gd determined by ICP and overall relaxivity of NP8. 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 















































S6.10 Characterization of NP9[Gd]/PEG//FA/Porph (1:0.05:0.05:0.05:0.5) 
 
              
      Figure S6.10-1 UV-vis spectrum of NP9.       Figure S6.10-2 TEM image of NP9. 
 
 
Figure S6.10-3 Relaxivity for NP9 between t = 0 and t = 2610 minutes for addition of Zn2+ (2 eq per 
Gd) in a transmetallation experiment at 37 °C.  
 
 
Figure S6.10-4 Cell viability of HeLa and MCF-7 cells incubated with different concentrations of 


































































Figure S6.10-5 EDX data for NP9. 
 
 





















































































Figure S6.10-9 NMRD profiles for NP9 at 25 and 37 °C. 
 
 
Table S6.10-1 Zeta potential and size of NP9. 
Zeta potential / mV − 33.4 
TEM diameter / nm 3.02 ± 0.63 
 
 
Table S6.10-2 Ratios of Au to Gd determined by ICP-OES and overall relaxivity of NP9. 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 














































S6.11 Characterization of NP10[Gd]/PEG/TG/FA/Porph (1:0.05:0.05:0.05:0.5) 
 
            
             Figure S6.11-1 UV-vis spectrum of NP10.     Figure S6.11-2 TEM image of NP10. 
 
 
Figure S6.11-3 Relaxivity for NP10 between t = 0 and t = 2610 minutes on addition of Zn2+ (2 eq per 
Gd) in a transmetallation experiment at 37 °C. 
 
 
Figure S6.11-4 Cell viability of HeLa and MCF-7 cells incubated with different concentrations of 































































































































































Figure S6.11-9 NMRD profiles of NP10 at 25 and 37 °C. 
 
 
Table S6.11-1 Zeta potential, DLS and size of NP10. 
Zeta potential / mV − 34.4 
TEM diameter / nm 2.82 ± 0.58 
Hydrodynamic diameter / nm 37.89 ± 12.86 
 
 
Table S6.11-2 Ratios of Au to Gd determined by ICP-OES and overall relaxivity of NP10. 
 Ratio (Au/Gd) NP r1 (10 MHz) at 37 °C 
NP8[Gd]/PEG/TG/FA/Porph 19:1 2090 
 
 











































S7. Summary of NMRD profiles 
 
The NMRD profiles were measured at 1H Larmor frequencies from 0.01 to 10 MHz using a Stelar 
SMARtracer™ FFC NMR relaxometer (0.25 T), equipped with a VTC90 temperature control unit. Each 
point was measured 8 times and if the deviation was outside 1% the measurement was repeated and the 
average value was taken. The measurements were made at 25 °C and 37 °C for each gold nanoparticle 
(AuNP) and the precise concentration of Gd3+ was determined using by ICP-OES. The r1 values were 
calculated using the below equation, with R1 being the relaxation rate measured, R1d the diamagnetic 
constant of the solvent and [CA] the concentration of Gd3+.  
 




Figure S7-1 NMRD profiles of NP1 – NP10 and 8 (labelled DOTAGA) per Gd unit at 25 °C (above) 




























NP7 [Gd] PEG Porph
NP8 [Gd] PEG TGlu Porph
NP9 [Gd] PEG Folic Porph





























NP7 [Gd] PEG Porph
NP8 [Gd] PEG TGlu Porph
NP9 [Gd] PEG Folic Porph








































































S8 Magnetic resonance imaging 
 
Magnetic resonance imaging was performed at 25 °C on a clinical 1.5 T MRI Scanner (Philips Ingenia, 
Philips Medical Systems) using a Modified Look-Locker Imaging (MOLLI) T1 sequence. The scan 
parameters were as follows: 15 x 300 x 300 mm field of view, 300 x 300 mm acquisition matrix, 3 mm 
slice thickness, 2.145 ms echo time, 4.290 ms repetition time and 50° flip angle. Each nanoparticle 
sample was prepared at gadolinium concentrations (ICP-OES) between 0.01 and 0.065 mM. The 1 mL 
phantoms were submerged in water during acquisition to reduce Gibbs artefacts. The T1 maps were 
analysed using Philips DICOM Viewer 3.0. T1 values were extracted for each nanoparticle sample 
across 5 slices and a mean average value was taken. R1 was then plotted against gadolinium 
concentration and the gradient of the straight line was taken to be the relaxivity. 
 
 
S9. ICP-OES and relaxivity data per nanoparticle summary 
 
ICP-OES analyses were performed on a Perkin Elmer Optima 2000 DV OES and 3 references were 
used (0.2, 5, 25 ppm solutions of the appropriate metal) in order to determine the precise concentration 
of the chosen metal. Prior to the measurement, the gold nanoparticles were digested in aqua regia at 
room temperature for a minimum of 3 hours before being diluted with water to reach a 10% 








































at 37 °C 
NP r1 (mM-1s-1) 
10 MHz 






NP1[Gd] Au3301Gd179 (18/1) 31.68 5691 4.08  0.67 16 
NP2[Gd]/PEG Au3018Gd118 (26/1) 31.44 3719 3.96  0.74 21 
NP3[Gd]/PEG/TG Au2516Gd61 (37/1) 37.96 2330 3.72  0.69 41 
NP4[Gd]/PEG/FA Au2502Gd169 (15/1) 28.83 4874 3.72  0.73 21 
NP5[Gd]/PEG/FA/TG Au2709Gd100 (27/1) 27.13 2932 3.83 0.59 18 
NP6[Gd]/Porph Au1033Gd87 (12/1) 42.21 3713 2.77  0.49 24 
NP7[Gd]/PEG/Porph Au874Gd67 (13/1) 40.88 2749 2.62  0.53 24 
NP8[Gd]/PEG/TG/Porph Au1235Gd67 (18/1) 40.24 2701 2.93  0.53 30 
NP9[Gd]/PEG/FA/Porph Au1338Gd80 (16/1) 34.72 2810 3.02  0.63 30 




S10 Time course study of cell uptake of GNP in HeLa and MCF-7 cells 
 
For cell uptake studies, cells were seeded into a 96-well plate (Corning® Costar®, Sigma-Aldrich) at a 
density of 15,000 cells per well and incubated for 24 h at 37 °C in a 5% CO2 incubator. The cells were 
then incubated with a 200 µM solution of the respective nanoparticle for a period of 1, 6 or 24 hours 
and in duplicates. The media was then removed and the cells were washed three times with PBS to 
ensure that all un-internalized nanoparticles had been removed. The cells were then fixed using a 4% 
formaldehyde solution and digested using aqua regia for at least 2 hours at room temperature. The 
digested solutions were then diluted with water to reach a 10% concentration of aqua regia and the gold 
concentration was measured using ICP-OES. 
 
Figure S10-1 Uptake in HeLa cells incubated with 200 M of NP1 - NP10 after 1, 6, 24 hours. 
 
 





































































The data in Figure 12 are quoted in GNP/mL to take into account the differing sizes of the NPs. This 
was calculated in the following manner: 
 
In preparing the samples for ICP-OES, the nanoparticles underwent a 7.5-fold dilution. Therefore, the 
gold concentrations (in mg/L), as determined by ICP-OES, were first multiplied by 7.5 to give gold 
concentration in each well. The volume of solution in each well was 200 µL, so dividing each value by 
5000 gave the mass of gold (in mg) in each well. These values were then divided by 15,000 (number of 
cells per well) to give mass of gold per cell. These values were then divided by the mass of the gold 
nanoparticle, to give number of nanoparticles per cell. 
The mass of each nanoparticle was calculated using the radius, as measured by TEM. First, the volume 




 𝜋 𝑟3    
The mass of each nanoparticle was calculated by multiplying the volume of the nanoparticle by the 






As an alternative, the data are shown below in terms of picograms per cell: 
 
 
Figure S10-3. Cell uptake studies (quoted in pg/cell) performed with NP1, NP5, NP7 and NP10 (200 























































S11 In vitro photodynamic therapy study 
 
HeLa cells were seeded into 8-well plates (Corning Costar, Sigma Aldrich) at a density of 30,000 cells 
per well and incubated for 24 h at 37 °C, in 5% CO2. The cells were then incubated with a 200 µM 
solution of the respective nanoparticle in media for a further 24 h. The media was then removed and the 
cells were washed 3 times with PBS before fresh media was added. Each well was then irradiated with 
a 570 nm laser, at 37 °C on a Zeiss-Axio Observer inverted microscope for a period of 5, 15 or 30 min. 
To measure cell viability, an MTT assay was performed whereby the media was replaced with a solution 
of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in PBS (2 mg/mL) before 
incubating the cells for 2 h. The solution was then replaced with DMSO before incubating the cells at 
room temperature, in the dark. Absorbance was measured at 570 nm, using a plate reader (SpectraMax 
M2/M2e Microplate Reader, Molecular Devices) and reported as a percentage, relative to the 
absorbance of cells that had been incubated with only media (no nanoparticles). 
 
 






















S12 Crystallographic data for porphyrin unit 
 
Crystal data for 15’: C56H49N5O4S2Zn·1.35(C4H8O), M = 1082.83, trigonal, R-3 (no. 148), a = b = 
50.2134(14), c = 11.0418(3) Å, V = 24110.7(15) Å3, Z = 18, Dc = 1.342 g cm–3, μ(Mo-Kα) = 0.593 mm–
1, T = 173 K, dark red blocks, Agilent Xcalibur 3 E diffractometer; 11584 independent measured 
reflections (Rint = 0.0412), F2 refinement,8,9 R1(obs) = 0.1039, wR2(all) = 0.2750, 8535 independent 
observed absorption-corrected reflections [|Fo| > 4σ(|Fo|), completeness to θfull(25.2°) = 99.9%], 636 
parameters. CCDC 1913151. 
 
The C46- and C52-based phenyl rings, and the O60-based coordinated tetrahydrofuran (THF) 
molecule in the structure of 15’ (formed by aerial oxidation of 15 during the crystallization experiment) 
were all found to be disordered, and in each case two orientations were identified, of ca. 67:33, 52:48 
and 67:33% occupancy respectively. The geometries of each pair of orientations were optimized, the 
thermal parameters of adjacent atoms were restrained to be similar, and only the non-hydrogen atoms 
of the major occupancy orientations were refined anisotropically (those of the minor occupancy 
orientations were refined isotropically). The presumed N27–H hydrogen atom could not be reliably 
located from ΔF maps, and so was added in a calculated position at an N–H distance of 0.90 Å. 
 
The included solvent was found to be highly disordered, and the best approach to handling this 
diffuse electron density was found to be the SQUEEZE routine of PLATON.10 This suggested a total 
of 974 electrons per unit cell, equivalent to 54.1 electrons per molecule. Before the use of SQUEEZE 
the solvent most resembled tetrahydrofuran (THF, C4H8O, 40 electrons), and 1.35 THF molecules 
corresponds to 54 electrons, so this was used as the solvent present. As a result, the atom list for the 
asymmetric unit is low by 1.35(C4H8O) = C5.4H10.8O1.35 (and that for the unit cell low by C97.2H194.4O24.3) 
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